COVID-19 Symptom Duration (Phase 2);Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phase 3);Number of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 2);Proportion of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 3);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2)

COVID-19 Symptom Duration (Phase 2);Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phase 3);Number of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 2);Proportion of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 3);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2)

COVID-19 symptom duration (Phase 2);Cumulative incidence of death due to any cause or hospitalization due to any cause (Phase 3);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 2);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2)

COVID-19 symptom duration (Phase 2);Cumulative incidence of death due to any cause or hospitalization due to any cause (Phase 3);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 2);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2)

Cumulative incidence of death from any cause or hospitalization (Phase 3);Duration of targeted clinical COVID-19 symptoms (Phase 2);Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2)

Cumulative incidence of death from any cause or hospitalization (Phase 3);Duration of targeted clinical COVID-19 symptoms (Phase 2);Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2);Quantification of SARS-CoV-2 RNA (Phase 2)

Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2);Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2);Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2);Cumulative incidence of death from any cause or hospitalization (Phase 3);Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2);Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3);Duration of COVID-19 symptoms (Phase 2);Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2)

Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2);Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2);Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2);Cumulative incidence of death from any cause or hospitalization (Phase 3);Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2);Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2);Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3);Duration of COVID-19 symptoms (Phase 2);Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2)